Browse Articles
Discover research articles across all indexed journals
A Compact 2-D photonic crystal biomedical sensor for enhanced glucose concentration detection in urine
Abstract This study introduces a 2-D Photonic Crystal (PhC) biosensor designed, simulated, and evaluated for detecting glucose concentrations in urine by utilizing refractive index variations. The sensor demonstrates exceptional performance, achieving a sensitivity of 20,040.30 nm/RIU for glucose levels ranging from 0–15 mg/dl, a quality factor of 10,424.55, and a detection limit as low as 8 × 10−10, surpassing benchmarks reported in the literature. With compact dimensions of 16.8 × 17.6 µm2 and compatibility with modern fabrication techniques, the proposed design is well suited for integration into portable diagnostic devices. A comprehensive comparative analysis underscores its superior sensitivity, ultra-high quality factor, and compact design, establishing it as a major advancement in glucose detection technology.
HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation.
539 Background: Clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation (sRCC) is associated with poor survival. Recent studies have shown downregulation of hypoxia-related pathways in sRCC (Motzer et al., Cancer Cell, 2020; El Zarif, Semaan et al., Cell Reports, 2024). In this study, we sought to compare HIF2α expression levels in ccRCC, with and without sarcomatoid differentiation and investigate clinical outcomes of patients (pts) with sRCC treated with HIF2α inhibitors (HIF2αi). Methods: To assess HIF2α gene expression in sRCC, RNA-seq data was collected from 2 clinical trials: JAVELIN Renal 101 (JR101), and IMmotion151 (IM151), as well as publicly available data from The Cancer Genome Atlas (TCGA). Mean HIF2α expression levels were compared between ccRCC with and without sRCC using Wilcoxon Rank-Sum test. To evaluate the clinical outcomes of pts with sRCC treated with HIF2αi, we also collected clinical data from pts with ccRCC who were treated with HIF2αi-based therapies (Belzutifan or AB521). Progression-free survival (PFS) and overall survival (OS) were analyzed using log-rank test and multivariable Cox regression model accounting for IMDC risk group, line of therapy, and type of regimen (HIF2αi; HIF2αi + Vascular endothelial growth factor-targeted therapy (VEGF-TT); HIF2αi + Immunotherapy (IO) + VEGF-TT). Results: RNA-seq data from 2,075 pts with renal cell carcinoma with a clear cell component from TCGA (48 sRCC; 493 ccRCC), JR101 (97 sRCC; 639 ccRCC) and IM151 (110 sRCC; 688 ccRCC) were included. Expression of EPAS1 , which encodes for HIF2α, was significantly downregulated in pts with sRCC in TCGA (log(TPM) mean: 6.63 vs 9.95 in ccRCC ; p < 0.001), JR101 (8.71 vs 8.93 in ccRCC ; p = 0.04) and IM151 (8.05 vs 8.69 in ccRCC ; p < 0.0001). For the clinical cohort, 104 pts treated with HIF2αi were included; 13.5% (14/104) had sRCC. In univariate analysis, sRCC was significantly associated with worse PFS (median PFS = 4.8 months (mo) vs 11.3 mo in ccRCC; p = 0.021) and numerically worse OS (20 mo vs 41.1 mo in ccRCC; p = 0.21). In multivariable analysis, sRCC was associated with worse PFS (HR adjusted : 2.55; 95% CI: 1.32–4.90; p=0.005) (Table) and numerically worse OS (HR adjusted : 2.14; 95% CI: 0.9–5.1; p=0.08). Conclusions: This study suggests that the efficacy of HIF2αi may be limited in sRCC, possibly due to decreased dependency on HIF2α signaling. Our findings highlight the need for novel therapeutic strategies in sRCC. Multivariable analysis for PFS. Variable HR adjusted 95%CI p-value sRCC (yes vs no) 2.55 1.32 – 4.91 0.005 HIF2αi line of therapy 1.32 1.04 – 1.65 0.018 IMDC group (favorable vs intermediate) 0.95 0.54 – 1.67 0.853 IMDC group (poor vs intermediate) 1.69 0.79 – 3.62 0.176 IMDC group (missing vs intermediate) 1.39 0.54 – 3.57 0.488 Regimen (VEGF-TT + HIF2αi vs HIF2αi) 0.64 0.30 – 1.37 0.251 Regimen (IO + VEGF-TT + HIF2αi vs HIF2αi) 0.23 0.03 – 1.95 0.179
Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
LBA138 Background: Mevrometostat (M) is a potent and selective inhibitor of EZH2. Dose exploration of M + enzalutamide (E) + androgen deprivation therapy (ADT) showed a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition, objective response (OR), and decline in prostate-specific antigen of ≥50% from baseline (PSA 50 ) in patients (pts) with mCRPC (NCT03460977). We report outcomes from the open-label, randomized, dose expansion part of this study. Methods: Pts with mCRPC who received prior abiraterone, ≤1 prior chemotherapy in any setting, with evidence of progression per modified Prostate Cancer Working Group 3 criteria were included. Pts receiving ADT were randomized 1:1 to M (orally, 1250 mg BID on empty stomach) + E (160 mg QD) or E, stratified by prior chemotherapy. Primary endpoints were radiographic progression-free survival (rPFS) per investigator assessment and safety. Secondary endpoints included OR by RECIST 1.1 (for pts with measurable disease at baseline), PSA 50 , and pharmacokinetics. Results: As of Sept 2, 2024,81 pts were included (M+E, n=41; E, n=40). Median (IQR) follow-up was 9.6 (3.1-14.5) mo. Median (range) age (yrs) was 70 (48-86) for M+E and 71.5 (50-86) for E. Overall, 43.9% of pts in the M+E group and 45.0% in the E group received prior taxane therapy. Median (95% CI) rPFS was 14.3 (7.5, not estimable) mo for M+E and 6.2 (4.1, 13.9) mo for E (hazard ratio 0.51; 90% CI 0.28, 0.95). In pts with measurable disease at baseline (M+E, n=15; E, n=14), OR rate (95% CI) was 26.7% (7.8, 55.1) for M+E (4 partial responses [PRs]) and 14.3% (1.8, 42.8) for E (2 PRs). Confirmed PSA 50 (95% CI) was observed in 34.1% (20.1, 50.6) of pts for M+E and 15.4% (6.0, 31.3) for E. Most common treatment-emergent adverse events (TEAEs) were diarrhea (78.0%), decreased appetite (58.5%), and dysgeusia (58.5%) for M+E, and asthenic conditions (42.5%), nausea (25.0%), and anemia (22.5%) for E. Grade ≥3 TEAEs were observed in 53.7% of pts in M+E (most common diarrhea, neutropenia and sepsis) and 42.5% in E. There were no treatment-related deaths. Geometric mean plasma exposures of M after multiple doses in combination with E were comparable for M 1250 mg on empty stomach and M 875 mg with food (AUC tau [h*ng/mL]: 1250 mg, 8733; 875 mg, 9631; C max [ng/mL]: 1250 mg, 2371; 875 mg, 1868). In M+E combination, M 875 mg with food had an improved safety profile compared with M 1250 mg on empty stomach. Conclusions: M+E shows improved outcomes vs E in pts with mCRPC, with a manageable AE profile. In M+E combination, M 875 mg with food has similar plasma exposure as M 1250 mg on empty stomach. Further investigation of M+E in pts with mCRPC is warranted. Disclosure: Pfizer's generative AI tool, MAIA, was used to draft this abstract (accessed: 2024-10-24); authors reviewed, edited, and take full responsibility for the content. Clinical trial information: NCT03460977 .
Radical cystectomy in female patients: Does the urinary diversion type affect postoperative complications?
752 Background: Data is limited on the possible impact of urinary diversion (UD) type on post cystectomy complications, particularly in women. This study aims to investigate this issue and identify predictors of post-cystectomy complications in female population. Methods: We utilized our prospectively maintained IRB-approved radical cystectomy (RC) database (#HS-01B014) to identify all female patients who underwent RC between 2003 and 2021. Patients were categorized into three groups based on their UD type: ileal conduit (IC), neobladder (NB) and continence cutaneous diversion (CCD). Demographics, baseline characteristics and postoperative complications were compared across the three groups. A multivariate logistic regression analysis was used to assess the predictors of complications at 90 days postoperatively. Results: A total of 531 female patients were included: 263 (49.5%) with IC, 206 (38.8%) with NB, and 62 (11.7%) with CCD. The table outlines the patients' demographics and perioperative characteristics. The overall 30-day complication rates were comparable across groups: 54.9% for NB, 51.6% for CCD, and 61.6% for IC (p = .195). Similarly, 90-day complication rates were also comparable (NB = 65.5%, CCD = 64.5%, IC = 70.3%; p = .456). 90-day complication subgroups including cardiac, pulmonary, gastrointestinal, hematologic, infectious, and neurologic were comparable between different UDs. However, genitourinary complications were significantly higher in CCD (32.3%) compared to IC (13.3%) and NB (14.6%) (p < .001). Multivariate analysis showed that patients with CCD had increased odds of 90-day genitourinary complications compared to NB (OR = 2.83 [95%CI: 1.38, 5.72], p= .001), while preoperative eGFR was protective (OR = 0.987 [95%CI; 0.977, 0.997], p = .010). Conclusions: Our results suggested that UD type has minimal influence on cumulative 30- and 90- day post-cystectomy complications. However, CCD was associated with an increased odds of 90-day genitourinary complications. Demographics and perioperative characteristics of patients stratified by urinary diversion type. Patient characteristics Neobladder(N = 206) Continent Cutaneous Diversion (N =62) Ileal conduit(N = 263) p Age (yrs.) 64.4 ± 9.8 64.2 ± 10.5 73.5 ± 10.4 <.001 Charleson Comorbidity Index 0 80 (38.8%) 25 (40.3%) 41 (15.6%) <.001 1 63 (30.6%) 11 (17.8%) 60 (22.8%) >=2 63 (30.6%) 26 (41.9%) 162 (61.6%) Preoperative eGFR (mL/min) 73.2 ± 24.7 72.3 ± 32.0 63.8 ± 29.0 <.001 Surgical Approach Open 196 (95.1%) 60 (96.8%) 177 (67.3%) <.001 Robotic assisted 10 (4.9%) 2 (3.2%) 86 (32.7%) Pathological Staging OC (< (y)pT2; pN0) 166 (80.6%) 44 (71.0%) 168 (63.9%) .002 EV (> (y)pT2; pN0) 26 (12.6%) 9 (14.5%) 62 (23.6%) LN+ (pN+) 14 (6.8%) 9 (14.5%) 33 (12.5%)
Climate change effects on ecosystem services: Disentangling drivers of mixed responses
Climate change is a pervasive hazard that impacts the supply and demand of ecosystem goods and services (EGS) that maintain human well-being. A recent review found that the impacts of climate change on EGS are sometimes mixed, posing challenges for managers who need to adapt to these changes. We expand on earlier work by exploring drivers of varying responses of EGS to climate within studies. We conducted a systematic review of English-language papers directly assessing climate change impacts on the supply, demand, or monetary value of ‘provisioning EGS’, ‘regulating EGS’, or ‘cultural EGS’. Ultimately, 44 papers published from December 2014 to March 2018 were analyzed. Nearly 66% of EGS were assessed for higher-income countries despite how lower-income countries disproportionately face negative climate impacts. Around 59% of observations or projections were mixed responses of EGS to climate change. Differences in climate impacts to EGS across space or climate scenarios were the most common causes of mixed responses, followed by mixed responses across time periods assessed. Disaggregating findings by drivers is valuable because mixed responses were often due to multiple drivers of variation. Carefully considering the decision context and desired outcome of a study will help select appropriate methodology to detect EGS variation. Although studies have often assessed relevant drivers of variation, assessing interactions of other sources of uncertainty and both climate and non-climate drivers may support more effective management decisions that holistically account for different values in the face of uncertainty.
IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment
Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review.
696 Background: The treatment landscape for genitourinary (GU) malignancies, including bladder, kidney, and prostate cancers, has evolved with several novel therapies approved in the past decade. The importance of mental health in patients with cancer is being more and more recognized in the past years. This study evaluates the monitoring of mental health and psychiatric symptoms in trials leading to FDA approvals for GU cancers. Methods: We comprehensively reviewed trial protocols and publications for FDA-approved GU cancer therapies from 2015-2024. For each approved therapy, we examined whether psychiatric side effects were monitored, the tools used, and the timing of assessments. Results: Of 42 trials for 31 approved treatments, 85% (36/42) monitored some psychiatric monitored psychiatric or mental health-related outcomes. EORTC QLQ-C30, EQ-5D-5L, and BPI-SF were the most common tools used for monitoring. However, 15% of trials did not assess mental health, and long-term follow-ups were inconsistent as described in the table. Depression and anxiety were the most evaluated symptoms. Nonetheless, the majority of the other psychiatric manifestations were not consistently assessed throughout trials. Conclusions: Psychiatric monitoring is present in many GU trials but remains inconsistent. Mental health assessments are typically part of broader quality-of-life evaluations rather than focused psychiatric tools. Future trials should adopt standardized psychiatric assessments to better manage patient well-being during treatment. Psychiatric symptoms monitoring in FDA-approved GU cancer trials - 2015 to 2024. Symptom Assessed (%) Baseline Long-Term Publications Prostate Kidney Bladder Depression 80% Yes Yes No Yes Yes Yes Anxiety 80% Yes Yes No Yes Yes Yes Insomnia 61% Yes Yes Yes Yes Yes Yes Cognitive Impairment 38% Yes Yes No Yes Yes Yes Irritability 38% Yes Yes No Yes Yes Yes Emotional Lability 9% Yes Yes No Yes No Yes Delirium 2% No No No No Yes No Psychosis 2% No No No No Yes No
Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.
219 Background: PROpel (NCT03732820) met its primary endpoint showing statistically significant investigator-assessed (INV) radiographic progression-free survival (rPFS) benefit with ola + abi vs pbo + abi in first-line mCRPC in pts enrolled irrespective of homologous recombination repair gene mutation (HRRm) status (intention-to-treat [ITT] hazard ratio [HR] 0.66, 95% CI 0.54–0.81; P <0.001). At final prespecified analysis (ITT), median overall survival (OS) with ola + abi vs pbo + abi was 42.1 vs 34.7 months (HR 0.81, 0.67–1.00; P =0.054). In pts assigned to HRRm subgroups using aggregated tumor tissue and circulating tumor DNA (ctDNA) test results ( post hoc analyses), the greatest benefit for ola + abi vs pbo + abi was in pts with BRCAm (rPFS HR 0.23, 0.12–0.43; OS HR 0.29, 0.14–0.56). Concordance based on HRRm status between tumor tissue and ctDNA testing was also high (80% +ve, 87% -ve predictive agreement). We report post hoc efficacy analyses in pts with BRCAm of germline (g) or somatic (s) origin. Methods: PROpel was a double-blind Phase III trial. Pts were randomized 1:1 to ola (300 mg twice daily [bid]) or pbo, and abi (1000 mg once daily) + prednisone/prednisolone (5 mg bid) until disease progression, unacceptable toxicity, or withdrawal of consent. Tumor BRCAm status was determined using aggregated results from tumor tissue (FoundationOne CDx) and ctDNA (FoundationOne Liquid CDx) tests, and g/s status by blood test (Myriad MyRisk). Results: Of the 85 BRCAm pts, 77 were evaluable for g/s status by blood test. Of these, 32% (n=25) had a BRCAm of g origin and 68% (n=52) of s origin. HRs for pts with g and s BRCAm for rPFS (INV 0.13 and 0.19, BICR 0.15 and 0.17) and OS (0.23 and 0.26) all favored ola + abi vs pbo + abi (Table). Conclusions: Ola + abi showed clinical benefit vs pbo + abi for rPFS and OS in pts with g or s BRCAm, supporting earlier findings in the overall BRCAm population of PROpel. Also, as g testing alone does not detect s mutations, these results highlight the importance of robust biomarker testing (which is currently underutilized in real-world practice), including tumor tissue or ctDNA testing, to inform treatment options. Clinical trial information: NCT03732820 . Germline BRCAm, (n=25) Somatic BRCAm, (n=52) Ola + Abi(n=15) Pbo + Abi (n=10) Ola + Abi (n=27) Pbo + Abi (n=25) rPFS* (INV, primary endpoint) Events, n (%) 5 (33.3) 10 (100) 7 (25.9) 17 (68.0) Median rPFS NR 6.9 NR 11.1 HR 0.13 (0.04–0.38) 0.19 (0.07–0.45) rPFS*(BICR, sensitivity analysis) Events 5 (33.3) 10 (100) 6 (22.2) 18 (72.0) Median rPFS NR 5.9 NR 9.1 HR 0.15 (0.05–0.45) 0.17 (0.06–0.41) OS † (key secondary endpoint) Events, n (%) 5 (33.3) 9 (90.0) 6 (22.2) 15 (60.0) Median OS NR 18.4 NR 27.5 HR 0.23 (0.07–0.67) 0.26 (0.09–0.65) *Primary analysis, DCO 30 July 2021; † Final prespecified analysis, DCO 12 Oct 2022. BICR, blinded independent central review; DCO, data cutoff; NR, not reached.
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer.
680 Background: The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is a tool used to describe a cancer patient’s functional status and recruit participants into clinical trials. Clinical trials recruit patients with a good performance status (ECOG 0 or 1) which is not concordant with the real-world population. ASCO-Friends of Cancer Research in a joint statement has recommended the inclusion of patients with reduced PS in clinical trials. We evaluated the inclusion of patients with ECOG 2 or greater in urothelial cancer clinical trials leading to FDA approvals between 2014 and 2024. Methods: The US Food and Drug Administration (FDA) website was searched for all the drugs or drug combinations approved for the treatment of urothelial cancer in the last 10 years. We used identifiers like the drug name, trial name, and registration number to retrieve data on participant ECOG scores from public databases. The data was then tabulated and trends were analyzed. Results: The US FDA approved 16 drugs and combinations for the treatment of urothelial cancer from 2014-2024. The trials for these drugs enrolled a total of 5621 participants, of which only 107 (1.9%) belonged to ECOG PS 2 or more. ECOG data was not available for OLYMPUS trial. Only one of the trials included 3 participants with ECOG 3. Five trials did not have any participants belonging to ECOG 2 or higher. Most of the trials had percentage enrollment of ECOG 2 <10% except EV-201. Conclusions: Participants with ECOG 2 and greater have minimal enrolment in registrational clinical trials of urothelial cancer. This limits the options available for treatment of urothelial cancer in patients with reduced PS. Greater inclusion of poor PS patients is needed in future trials for greater health equity. Clinical trial Year Reduced PS% (ECOG 2 or higher) QUILT-3.0320 2024 3.5% BLC3001 2024 9.4% EV-302/KN-A39 2023 2.9% nadofaragene firadenovec-vncg 2022 2.5% CHECKMATE-274 2021 2.3% EV-201 2019 12.4% JNJ-42756493 2019 7.1% KEYNOTE-045 2017 1.1% CHECKMATE-901, EV-301, TROPHY, JAVELIN Bladder 100, KEYNOTE-057, durvalumab, atezolizumab 2016-2024 <1%
Automated gait event detection for exoskeleton-assisted walking using a long short-term memory model with ground reaction force and heel marker data
Traditional gait event detection methods for heel strike and toe-off utilize thresholding with ground reaction force (GRF) or kinematic data, while recent methods tend to use neural networks. However, when subjects’ walking behaviors are significantly altered by an assistive walking device, these detection methods tend to fail. Therefore, this paper introduces a new long short-term memory (LSTM)-based model for detecting gait events in subjects walking with a pair of custom ankle exoskeletons. This new model was developed by multiplying the weighted output of two LSTM models, one with GRF data as the input and one with heel marker height as input. The gait events were found using peak detection on the final model output. Compared to other machine learning algorithms, which use roughly 8:1 training-to-testing data ratio, this new model required only a 1:79 training-to-testing data ratio. The algorithm successfully detected over 98% of events within 16ms of manually identified events, which is greater than the 65% to 98% detection rate of previous LSTM algorithms. The high robustness and low training requirements of the model makes it an excellent tool for automated gait event detection for both exoskeleton-assisted and unassisted walking of healthy human subjects.
Contrast-enhanced magnetic resonance imaging based calf muscle perfusion and machine learning in peripheral artery disease
Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study.
706 Background: Avelumab 1LM is standard of care for patients with la/mUC without disease progression after 1L platinum-based chemotherapy (PBC) based on results from the JAVELIN Bladder 100 phase 3 trial. The AVENUE study is evaluating the effectiveness and safety of avelumab 1LM treatment in routine clinical practice in Germany, Spain, Switzerland, and Russia. Previous results showed the acceptable safety profile of avelumab 1LM in a heterogeneous real-world population. Here, we report initial effectiveness data and updated baseline and safety data from the second interim analysis. Methods: AVENUE is a prospective, noninterventional study in patients with la/mUC without disease progression after 1L PBC. Initiation of avelumab 1LM is decided by the treating physician prior to enrollment per local approval. Patients are followed for 36 mo. The primary objective is to evaluate the overall survival (OS) rate at 12, 24, and 36 mo. Secondary objectives include assessment of median OS, progression-free survival (PFS), tumor response, and safety. Results: By data cutoff (May 9, 2024), 177 patients had received avelumab 1LM (median follow-up, 10.0 mo). Median age was 70 years (range, 43-89) and 78% were male. ECOG PS was 0-1 in 89.3%, ≥2 in 5.1%, and not reported (NR) in 5.6%. Primary tumor site was upper or lower tract in 28.2% and 71.8%, respectively. 1L PBC regimen was gemcitabine + cisplatin in 61.0% (split dose in 8.5%), gemcitabine + carboplatin in 36.2%, and other/switch in 3.4%. Number of prior PBC cycles was <4, 4-6, >6, and NR in 12.4%, 84.2%, 2.8%, and 0.6%, respectively. Median time to avelumab 1LM initiation was 6.1 weeks (range, 0.3-80.4) and median treatment duration was 6.0 mo (range, 0.5-30.8). Median OS was not reached (95% CI, 17.0-not estimable) and 6- and 12-mo OS rates (95% CI) were 80.6% (73.9-85.7) and 69.1% (61.1-75.7), respectively. Median PFS was 5.8 mo (95% CI, 4.6-9.1) and 6- and 12-mo PFS rates (95% CI) were 50.0% (42.1-57.3) and 33.1% (25.2-41.2). Disease control rate (assessed up to 6 mo) was 66.9% (95% CI, 58.8-74.3). Treatment-related adverse events (TRAEs) occurred in 57.6%, were grade ≥3 in 15.8%, serious in 15.3%, and led to permanent discontinuation in 10.7%. The most common TRAEs of any grade (≥4.0%) were fatigue (9.6%), hyperthyroidism (5.1%), pruritus (4.5%), and diarrhea (4.0%). Grade ≥3 immune-related AEs and infusion-related reactions occurred in 6.2% and 3.4%, respectively. At last follow-up, 28.8% of patients remained on avelumab, and 34.5% and 8.5% had received second- or third-line treatment (enfortumab vedotin in 21.5% and 2.3%), respectively. Conclusions: Data from the second interim analysis of AVENUE confirm the effectiveness and acceptable safety profile of avelumab 1LM in patients with la/mUC treated in routine clinical practice, consistent with previous studies.
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
667 Background: A critical need persists to develop treatments for BCG-unresponsive (BCG-U) non-muscle invasive bladder cancer (NMIBC) patients (pts). The intravesical gemcitabine plus docetaxel (Gem/Doc) doublet and intravenous agents targeting the PD-(L)1 immune checkpoint have both demonstrated complete responses (CRs) in BCG-U NMIBC investigations. With this knowledge, we aimed to assess the clinical efficacy and safety of durvalumab (D) in combination with intravesical Gem/Doc. Methods: The multi-arm, multi-stage ADAPT-BLADDER trial design has been previously described (Hahn NM et al, Eur Urol 2023). Here, we report outcomes from the D + Gem/Doc (cohort 4) phase 1 and phase 2 expansion arms. In phase 1, BCG-U NMIBC patients were enrolled in a 6 + 3 + 3 fashion to establish safety. In phase 2, additional patients were enrolled to evaluate the primary endpoint of CR rate in the total study population and to provide a CR rate estimate within the subset of patients with CIS. Per protocol, phase 1 and 2 efficacy analyses were combined. Enrollment of pure papillary patients was capped to ensure at least 20 patients with CIS. Patients received D 1500 mg iv on day 1 of each 4-week cycle for up to 6 cycles. In addition, they received intravesical Gem 1000 mg + Doc 37.5 mg weekly for the first 6 weeks. Patients achieving a CR were encouraged, but not required, to receive Gem/Doc monthly maintenance therapy. Cystoscopic and urine cytology assessments were performed every three months in year one with a mandatory biopsy at 12-months in responding patients. Toxicity rates were reported per CTCAE v5.0. Results: Between 1/2022-10/2024, 40 pts enrolled (12 phase 1, 28 phase 2) from 6 sites. The study completed its full planned accrual. Demographics included: median age 69 years; 83% male; CIS (8 pts), high-grade (HG) T1 + CIS (7 pts), HG Ta + CIS (6 pts), HG Ta (13 pts) and HG T1 (6 pts). No dose limiting toxicities were observed in the phase 1 portion. Among 27 patients (15 CIS, 12 papillary) evaluable for response at the August 2024 data lock, a CR was observed in 24 patients (89%) (CIS – 13/15 (87%); Papillary – 11/12 (92%)). Evaluation of pts still receiving study treatment for CR and durability of response is ongoing. One pt (4%) progressed to muscle invasion on study treatment. Highest grade treatment-related adverse events observed were grade 1 – 12 (36%) pts, grade 2 – 11 (33%) pts, grade 3 – 2 (6%) pts (sepsis n=1, pneumonitis n=1), and grade 4 – 1 (3%) pt (cough n=1) respectively. One on-study death due to retroperitoneal bleed unrelated to study therapy was observed. Conclusions: Combination treatment with durvalumab plus intravesical gemcitabine and docetaxel demonstrates promising clinical efficacy with a high complete response rate. Observed adverse event type, frequency, and severity were consistent with prior durvalumab trial experiences. Clinical trial information: NCT03317158 .
Evaluating RSPO2 activation and its association with outcomes and potential role as a driver in double-negative prostate cancer (DNPC).
236 Background: Several aggressive tumor variants have emerged since the broad use of 2nd generation androgen therapies for metastatic prostate cancers (mPCs). Close to 20% of mPCs are double negative prostate cancers (DNPC) that lack androgen receptor (AR) and do not exhibit histopathological features of neuroendocrine prostate cancer (NEPC). Our study focused on the R-spondin family of genes ( RSPO1/2/3/4 ), which are secreted proteins classified as WNT regulators. In mPCs, we examined their genomic alterations, impact on clinical outcomes, interaction with CTNNB1 (master regulator of WNT signaling), or other genes associated with DNPC and epithelial-mesenchymal transition (EMT). Methods: Alterations in RSPOs , CTNNB1 , and APC were examined with respect to survival using data from the TCGA Pan Cancer Atlas (n=10967) and a non-redundant set of prostate tumors from cBioPortal (n=2510). Kaplan-Meier and log-rank tests were used to evaluate survival. Alphafold2 was used to model the protein structures in silico . Differential gene expression, Algorithm for Linking Activity Networks (ALAN), and Gene Set Enrichment Analysis (GSEA) were used to model gene expression and determine enriched pathways. Proliferative effects of RSPO2 and CTNNB1 were analyzed in AR+ (LNCaP) and AR- (PC3) cell lines. Results: Pan cancer RSPO2 amplification rates (5%) were greater than CTNNB1 mutations (4%) but less than APC loss (8%). In mPC, RSPO2 amplifications (22%) were greater than CTNNB1 mutations or APC loss (9%, 8%). RSPO1/3/4 alterations were of low prevalence. Pan cancer, RSPO2 and CTNNB1 alterations were associated with poor disease-free survival (HR=1.578, 1.448, 95%CI=1.17-2.13, 1.06-1.964, p<0.001 respectively), whereas APC loss or RSPO1/3/4 alterations were not prognostic. In primary prostate cancer, RSPO2 amplifications were associated with worse survival (HR=1.63, 95%CI=1.05-2.54, p<0.05). In silico protein structure modeling indicated stark differences between RSPO2 and RSPO1/3/4 . Using RNA-seq data from 208 mPCs, our gene-gene interaction analysis and GSEA indicated that RSPO2 expression was robustly associated with DNPC driver genes FGFR1/2 , the Hallmark EMT pathway, and EMT transcription factors ZEB1 , SNAI1/2 , TWIST1/2 , while being anti-correlated with expression of AR, AR co-factors ( FOXA1 , HOXB13 ), and Hallmark androgen signaling. Unlike RSPO2 , CTNNB1 was associated with Hallmark EMT and Androgen response. Finally, RSPO2 overexpression promoted proliferation in the two PC cell lines regardless of AR expression. Conclusions: RSPO2 has unique features from RSPO1/3/4 in which amplifications are associated with worse outcomes in prostate and other cancers. Relative to CTNNB1 , RSPO2 exhibits unique signaling properties that imply RSPO2 has oncogenic functions other than WNT signaling, which may explain how it promotes growth of cell lines without AR expression.
Classifying COVID-19 hospitalizations in epidemiology cohort studies: The C4R study
Rationale Robust COVID-19 outcomes classification is important for ongoing epidemiology research on acute and post-acute COVID-19 conditions. Protocolized medical record review is an established method to validate endpoints for clinical trials and cardiovascular epidemiology cohorts; however, a protocol to adjudicate hospitalizations for COVID-19 among epidemiology cohorts was lacking. Objectives We developed a protocol to ascertain and adjudicate hospitalized COVID-19 across a meta-cohort of 14 US prospective cohort studies. This report describes the first three years of protocol implementation (October 1, 2020—October 1, 2023) and evaluates its repeatability and performance compared to classification by administrative codes. Methods The protocol was adapted from cohort approaches to clinical cardiovascular events ascertainment and adjudication. Potential COVID-19 hospitalizations and deaths were identified by self-/proxy-report and, in some cases, active surveillance. Medical records were requested from hospitals and adjudicated for COVID-19 outcomes by clinically trained personnel according to a standardized rubric. Inter-rater agreement was assessed. The sensitivity and specificity of discharge diagnosis codes was compared to adjudicated diagnoses. Measurements and main results The study obtained medical records for 1,167 potential COVID-19 hospitalizations, which underwent protocolized adjudication. Adjudication confirmed COVID-19 infection was present for 1,030 (88%) events, of which COVID-19 was not the cause of hospitalization for 78 (8%). Of 952 hospitalizations determined by adjudicators to be caused by COVID-19, 319 (34%) participants were critically ill and 210 (22%) died. Pneumonia was confirmed in 822 (86%) and acute kidney injury in 350 (37%); other cardiovascular and thrombotic complications were rare (2–5%). Interrater reliability among adjudicators was high (kappa = 0.85–1.00) except for myocardial infarction (kappa = 0.60). Compared to adjudication, sensitivity of discharge diagnosis codes was higher for pneumonia (84%) and pulmonary embolism (81%) than for other complications (48–70%). Conclusions Protocolized adjudication confirmed four out of five COVID-19 hospitalizations in a US meta-cohort and confirmed cases of pneumonia, pulmonary embolism, and other conditions that were not indicated by discharge diagnosis codes. These results highlight the importance of validating health outcomes for use in research on COVID-19 and post-COVID-19 conditions, and some limitations of claims-based data.
Spin-dependent thermoelectric properties of a hybrid ferromagnetic metal/quantum dot/topological insulator junction
Abstract The thermoelectric properties of hybrid system based on a single-level quantum dot coupled to a ferromagnetic metallic lead and attached to the surface states of a three-dimensional topological insulator are theoretically investigated. On the surface of a three-dimensional topological insulator, massless helical Dirac fermions emerge. We calculate the thermoelectric coefficients, including electrical conductance, Seebeck coefficient (thermopower), heat conductance, and the figure of merit, using the nonequilibrium Green’s function technique. The results are analyzed in terms of the emergence of new effects. The calculations are performed within the Hubbard I approximation concerning the dot’s Coulomb interactions. Additionally, the spin-dependent coupling of the quantum dot to the ferromagnetic lead lifts the spin degeneracy of the dot’s level, which influences the transport properties of the system. We incorporate this effect perturbatively to obtain the spin-dependent renormalization of the dot’s level. We also consider the case of finite spin accumulation in the ferromagnetic electrode, which leads to spin thermoelectric effects.
Concordance of circulating tumor DNA and imaging surveillance in patients with urothelial carcinoma and renal cell carcinoma post-immunotherapy.
597 Background: Early detection of recurrence in urothelial carcinoma (UC) and renal cell carcinoma (RCC) may improve patient outcomes. Conventional imaging techniques may not identify early molecular relapses that precede clinical relapse. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of disease relapse. This study aims to evaluate the concordance of molecular relapses by ctDNA and radiographic progression in patients with UC and RCC who are off immunotherapy due to intolerance of side effects or completion of treatment. Methods: We conducted a retrospective study of locally advanced/advanced UC and RCC patients who were treated at The Ohio State University James Cancer Hospital from November 2021 to September 2024. Patients who completed planned immunotherapy followed by imaging and ctDNA surveillance were included. ctDNA levels were measured using the Signatera tissue informed assay at intervals of 4 to 12 weeks. Imaging surveillance schedules were at the treating physician discretion. Patient demographics, clinical characteristics, and ctDNA levels were recorded and analyzed. Results: A total of 36 patients were included: muscle-invasive bladder cancer (MIBC, n = 10), metastatic urothelial carcinoma (mUC, n = 10), locally advanced RCC (n = 4), and metastatic RCC (mRCC, n = 12). The median follow-up was 39.5 weeks (range: 1–138 weeks), with a median age of 67.5 years (range: 41–83 years), and 72.2% were male. At the time of immunotherapy discontinuation, ctDNA was negative in all patients except one mRCC patient (ctDNA 0.95 MTM/mL). During surveillance, 9 patients (25%) - 5 mUC and 4 mRCC - became ctDNA-positive, of which, eight showed radiographic progression, while one mRCC patient (ctDNA 0.15 MTM/mL) did not. None of the 27 patients (75%) that continued to have negative ctDNA had radiographic progression. For the 8 patients with progression, the median time from stopping immunotherapy to ctDNA relapse was 17.5 weeks (range: 11–42 weeks). The median time from ctDNA relapse to imaging-confirmed progression was 22 weeks (range: 13–43 weeks). At progression, ctDNA levels ranged from 0.08 to 136.49 MTM/mL (median: 2.33 MTM/mL). Six of the 20 metastatic patients (30%) relapsed despite negative ctDNA at immunotherapy discontinuation. Conclusions: ctDNA positivity occurs much earlier and is highly concordant with radiographic progression in patients with locally advanced/advanced UC and RCC under post-immunotherapy surveillance. These findings suggest that ctDNA is a promising tool for early disease relapse detection in these patients. Further studies are warranted to validate these results and establish standardized ctDNA surveillance protocols.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
476 Background: Brain metastasis (BM) is an adverse prognostic indicator and associated with poor survival for patients with metastatic renal cell carcinoma (mRCC). Although immune checkpoint inhibitor (ICI) therapy has significantly improved survival in patients with metastatic renal cell carcinoma, the prognostic significance of BM in the ICI era is unclear. Methods: We performed a retrospective cohort study of patients diagnosed with clear cell RCC (ccRCC) between 2012-2023 at the Yale Cancer Center. We examined the association between brain metastasis and overall survival among patients by treatment type (with or without ICI in any line of therapy). We compared overall survival (mOS) using Kaplan-Meier analyses and multivariable Cox proportional hazards models. Results: We identified 338 patients diagnosed with metastatic ccRCC between 2012 and 2023, of whom 96 (28.4%) had BM, 39 of which were detected by screening versus 57 detected by symptoms. BM detected on screening MRI were smaller than those identified for cause (mean 13.9 versus 20.8 mm, respectively, p=0.002). The mOS from the time of metastatic ccRCC diagnosis was 54.0 months (95%CI 41-76) in patients without BM versus 37.0 (27-52) months in patients with BM (p=0.03). Among patients who received ICI therapy, mOS was 66 months (95% CI, 50-91) in those without BM versus 37 months (95% CI, 29-63) in those with BM (p=.01). In patients who did not receive ICI therapy, mOS was 31.5 months (95% CI, 23-80) in those without BM versus 17 months (95% CI, 14-NR) in those with BM (p=0.4). Among patients with BM, the mOS from the development of BM was 17.0 months (95% CI, 13-30). Median overall survival was 62 (95% CI: 17-NR months) versus 12 months (95% CI: 5-25 months) from the time of metastatic cancer diagnosis for those who underwent screening versus those who did not (p=0.0001). Conclusions: In our ccRCC population, there is a higher prevalence of brain metastases than previously thought. Overall survival for patients with metastatic ccRCC and brain metastases has improved in the era of ICI therapy. Brain metastases remain associated with poor prognosis and were frequently detected during asymptomatic screening. Patients with brain metastases discovered on screening had improved overall survival compared to those with brain metastases discovered because of symptoms.
MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer
In the last decade, advancements in understanding the genetic landscape of lung squamous cell carcinoma (LUSC) have significantly impacted therapy development. Immune checkpoint inhibitors (ICI) have shown great promise, improving overall and progression-free survival in approximately 25% of the patients. However, challenges remain, such as the lack of predictive biomarkers, difficulties in patient stratification, and identifying mechanisms that cancers use to become immune-resistant (“immune-cold”). Analysis of TCGA datasets reveals reduced MAP1LC3C expression in cancer. Further analysis indicates that low MAP1LC3C is associated with reduced CIITA and HLA expression and with decreased immune cell infiltration. In tumor cells, silencing MAP1LC3C inhibits CIITA expression and suppresses HLA class II production. These findings suggest that cancer cells are selected for low MAP1LC3C expression to evade efficient immune responses.